| scholarly article | Q13442814 |
| P2093 | author name string | A Trkola | |
| J M Binley | |||
| J P Moore | |||
| J E Robinson | |||
| T R Fouts | |||
| P2860 | cites work | Genotypic and phenotypic characterization of HIV-1 patients with primary infection | Q22242245 |
| Identification of a major co-receptor for primary isolates of HIV-1 | Q22251282 | ||
| A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors | Q28118386 | ||
| The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates | Q28282895 | ||
| CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 | Q28646859 | ||
| HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 | Q29616094 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
| Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes | Q29619514 | ||
| High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates | Q33760671 | ||
| Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain | Q33880904 | ||
| Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein | Q33937274 | ||
| Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein | Q34097650 | ||
| Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 | Q34292765 | ||
| Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein | Q34301897 | ||
| Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera | Q35828529 | ||
| A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. | Q35828898 | ||
| Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein | Q35833979 | ||
| Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. | Q35839973 | ||
| Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. | Q35841780 | ||
| Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding | Q35845976 | ||
| Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. | Q35849408 | ||
| Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. | Q35857331 | ||
| The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus | Q42817327 | ||
| Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera. | Q45770199 | ||
| Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. | Q52449889 | ||
| A trimeric structural domain of the HIV-1 transmembrane glycoprotein | Q54155492 | ||
| Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. | Q55487007 | ||
| Back to primary school | Q60075598 | ||
| Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4 | Q68515930 | ||
| A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates | Q71185106 | ||
| Expression and Characterization of CD4-IgG2, a Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates | Q71783840 | ||
| Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1 | Q72417361 | ||
| Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody | Q35866030 | ||
| Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses | Q35868205 | ||
| Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells | Q35879840 | ||
| Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer | Q36365085 | ||
| Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. | Q36366296 | ||
| Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies | Q36620408 | ||
| Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. | Q36623941 | ||
| Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. | Q36627098 | ||
| Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. | Q36628256 | ||
| Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization | Q36635390 | ||
| Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans | Q36641374 | ||
| Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding | Q36649958 | ||
| Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains | Q36653730 | ||
| Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons | Q36655953 | ||
| Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates | Q36656036 | ||
| Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody | Q36687562 | ||
| Changes in both gp120 and gp41 can account for increased growth potential and expanded host range of human immunodeficiency virus type 1 | Q36699051 | ||
| V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1 | Q36711168 | ||
| Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody | Q36821885 | ||
| Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans | Q37548597 | ||
| Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor | Q37588188 | ||
| Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody | Q37603996 | ||
| Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. | Q39313957 | ||
| HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain | Q39313963 | ||
| Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding | Q39485924 | ||
| CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. | Q39605077 | ||
| Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. | Q39868309 | ||
| Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. | Q39874632 | ||
| Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. | Q40038277 | ||
| Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody | Q40062738 | ||
| Candidate AIDS vaccines | Q40416583 | ||
| Toward an understanding of the correlates of protective immunity to HIV infection | Q40941051 | ||
| HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. | Q41120023 | ||
| CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. | Q41151327 | ||
| Neutralization of SIVmac239/17E in lymphocyte cultures involves virus strain-specific linear and conformational epitopes encoded by different regions of the env gene including the "V3" domain | Q41179656 | ||
| Antigenic determinants on HIV-1 envelope glycoproteins: a dickens of a time with oligomer twist | Q41179665 | ||
| Increase in sensitivity to soluble CD4 by primary HIV type 1 isolates after passage through C8166 cells: association with sequence differences in the first constant (C1) region of glycoprotein 120. | Q41364323 | ||
| Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. | Q41550657 | ||
| Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein | Q41645847 | ||
| Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120 | Q42129803 | ||
| Characterization of murine monoclonal antibodies to HIV-1 induced by synthetic peptides | Q42649550 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| antibody | Q79460 | ||
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 2779-2785 | |
| P577 | publication date | 1997-04-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex | |
| P478 | volume | 71 |
| Q55383445 | A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. |
| Q27655865 | A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies |
| Q34357078 | A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response |
| Q39537121 | A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. |
| Q36363866 | A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays |
| Q39588870 | A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure |
| Q47982875 | A role for carbohydrates in immune evasion in AIDS |
| Q36037760 | A vaccine for HIV type 1: The antibody perspective |
| Q33743663 | AIDS and HIV vaccines |
| Q45746959 | Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies |
| Q27469855 | Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6 |
| Q27640463 | Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity |
| Q33784679 | An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades |
| Q45761069 | An Investigation of the High-Avidity Antibody Response to Glycoprotein 120 of Human Immunodeficiency Virus Type 1 |
| Q33272711 | An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10 |
| Q36549220 | Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein |
| Q53877712 | Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins |
| Q39305772 | Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization |
| Q28256508 | Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env |
| Q24536059 | Antibody vs. HIV in a clash of evolutionary titans |
| Q33850612 | Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition |
| Q33849237 | Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion |
| Q36447540 | Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design |
| Q34050712 | Assessment of HIV vaccine development: past, present, and future |
| Q37059589 | Binding of Human Immunodeficiency Virus Type 1 to Immature Dendritic Cells Can Occur Independently of DC-SIGN and Mannose Binding C-Type Lectin Receptors via a Cholesterol-Dependent Pathway |
| Q39029460 | Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection |
| Q61815651 | CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity |
| Q28646881 | CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization |
| Q33640139 | Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2) |
| Q34471760 | Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region |
| Q39592994 | Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein |
| Q33785114 | Characterization of Simian-Human Immunodeficiency Virus Envelope Glycoprotein Epitopes Recognized by Neutralizing Antibodies from Infected Monkeys |
| Q80171295 | Characterization of the antibody response elicited by HIV-1 Env glycomutants in rabbits |
| Q41493875 | Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker |
| Q33854138 | Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. |
| Q39484948 | Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates |
| Q52721542 | Comparison of Uncleaved and Mature Human Immunodeficiency Virus (HIV-1) Membrane Envelope Glycoprotein Trimers. |
| Q39549660 | Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected i |
| Q34461554 | Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120. |
| Q36499053 | Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. |
| Q37059997 | Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes |
| Q33813526 | Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope |
| Q45744862 | Crossreactive neutralizing antibodies induced by immunization with caprine arthritis-encephalitis virus surface glycoprotein |
| Q33788810 | Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains |
| Q27644383 | Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env |
| Q27657377 | Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications |
| Q44831372 | DNA vaccination for HIV. |
| Q35060140 | Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system |
| Q39579260 | Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies |
| Q33821658 | Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo |
| Q37042563 | Development of prophylactic vaccines against HIV-1. |
| Q38989507 | Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits |
| Q92828111 | Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function |
| Q40839976 | Emerging studies of human HIV-specific antibody repertoires |
| Q33843103 | Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. |
| Q34466693 | Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. |
| Q38581943 | Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens |
| Q33839485 | Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys |
| Q35076987 | Enzyme Digests Eliminate Nonfunctional Env from HIV-1 Particle Surfaces, Leaving Native Env Trimers Intact and Viral Infectivity Unaffected |
| Q33883887 | Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 |
| Q37596817 | Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope |
| Q31016969 | Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. |
| Q28217208 | Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. |
| Q28743199 | Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1) |
| Q28292389 | Galectin-1 and HIV-1 Infection |
| Q45749447 | Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA. |
| Q33842152 | Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development |
| Q37145333 | Glycosphingolipid composition of human immunodeficiency virus type 1 (HIV-1) particles is a crucial determinant for dendritic cell-mediated HIV-1 trans-infection |
| Q40843036 | HIV gp120: double lock strategy foils host defences |
| Q37059216 | HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant |
| Q39402539 | HIV-1 Virus-Like Particles Bearing Pure Env Trimers Expose Neutralizing Epitopes but Occlude Nonneutralizing Epitopes |
| Q35988809 | HIV-1 and the hijacking of dendritic cells: a tug of war. |
| Q33601938 | HIV-1 attachment: another look. |
| Q29619017 | HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites |
| Q34337263 | High frequency of virus-specific B lymphocytes in germinal centers of simian-human immunodeficiency virus-infected rhesus monkeys |
| Q35531320 | Host-soluble galectin-1 promotes HIV-1 replication through a direct interaction with glycans of viral gp120 and host CD4. |
| Q36076117 | Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein |
| Q35892184 | Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off |
| Q30424366 | Human immunodeficiency virus vaccine trials |
| Q24679395 | Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design |
| Q39860657 | Identification of a feline leukemia virus variant that can use THTR1, FLVCR1, and FLVCR2 for infection |
| Q37157165 | Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation |
| Q33811940 | Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate |
| Q33835295 | Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. |
| Q24531479 | Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines |
| Q39550518 | Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV |
| Q41093377 | Increased Incorporation of Chimeric Human Immunodeficiency Virus Type 1 gp120 Proteins into Pr55gagVirus-like Particles by an Epstein–Barr Virus gp220/350-Derived Transmembrane Domain |
| Q40883803 | Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker |
| Q47364595 | Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization |
| Q34142795 | Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization |
| Q40096483 | Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops |
| Q34983331 | Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. |
| Q40468582 | Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers. |
| Q35647772 | Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer |
| Q36103090 | Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens |
| Q37370393 | Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Δc(BaL.). |
| Q33984358 | Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains |
| Q33374701 | Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120 |
| Q40940339 | Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on Gp41 in HIV-1-infected patients. |
| Q38589314 | Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations |
| Q33785510 | Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. |
| Q41027043 | Mechanisms of Resistance of HIV-1 Primary Isolates to Complement-Mediated Lysis |
| Q27322437 | Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa |
| Q34347265 | Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein |
| Q34070049 | Mutation-directed chemical cross-linking of human immunodeficiency virus type 1 gp41 oligomers. |
| Q36565090 | N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus |
| Q34434854 | Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. |
| Q33369086 | Net positive charge of HIV-1 CRF01_AE V3 sequence regulates viral sensitivity to humoral immunity |
| Q33782556 | Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity |
| Q83518445 | Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral theraphy |
| Q45460445 | Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability. |
| Q33783516 | Neutralizing Antibodies in Sera from Macaques Infected with Chimeric Simian-Human Immunodeficiency Virus Containing the Envelope Glycoproteins of either a Laboratory-Adapted Variant or a Primary Isolate of Human Immunodeficiency Virus Type 1 |
| Q34550046 | Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success |
| Q30431941 | Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140 |
| Q39699375 | Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site |
| Q31039719 | Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library |
| Q30436401 | Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies |
| Q34343380 | Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q33852768 | Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge |
| Q36540060 | Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked |
| Q36890056 | Presence of Host ICAM-1 in Human Immunodeficiency Virus Type 1 Virions Increases Productive Infection of CD4 + T Lymphocytes by Favoring Cytosolic Delivery of Viral Material |
| Q36974754 | Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. |
| Q36954218 | Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras |
| Q36559735 | Proteolytic Processing of the Human Immunodeficiency Virus Envelope Glycoprotein Precursor Decreases Conformational Flexibility |
| Q42166543 | Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. |
| Q39484956 | Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate |
| Q41093372 | Recombinant Human Immunodeficiency Pr55gagVirus-like Particles Presenting Chimeric Envelope Glycoproteins Induce Cytotoxic T-Cells and Neutralizing Antibodies |
| Q36837815 | Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization |
| Q40468601 | Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. |
| Q32157141 | Simian Immunodeficiency Virus (SIV) Envelope-Specific Fabs with High-Level Homologous Neutralizing Activity: Recovery from a Long-Term-Nonprogressor SIV-Infected Macaque |
| Q40311562 | Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma |
| Q34334135 | Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins |
| Q30490942 | Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. |
| Q33680601 | Strategies used by human immunodeficiency virus that allow persistent viral replication |
| Q39603597 | Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes |
| Q36856960 | Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors |
| Q44572417 | Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. |
| Q27629806 | Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates |
| Q33785383 | Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting |
| Q33845503 | Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages |
| Q34317025 | The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection |
| Q27469663 | The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts |
| Q40414065 | The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles |
| Q34341843 | The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. |
| Q35644971 | The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization |
| Q33953062 | The role of the third β strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012 |
| Q77810540 | Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group |
| Q42572387 | Topological Analysis of HIV-1 Glycoproteins Expressed In Situ on Virus Surfaces Reveals Tighter Packing but Greater Conformational Flexibility than for Soluble gp120 |
| Q35531553 | Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus |
| Q40773199 | Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates |
| Q41717140 | Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection? |
Search more.